Umbilical cord-blood transplantations from unrelated donors in patients with inherited metabolic diseases: Single-institute experience

Pediatric Transplantation

Volumn 12, Issue 6, 2008, Pages 672-676

  Tokimasa, Sadao ^a   Ohta, Hideaki ^a   Takizawa, Sachiko ^a   Kusuki, Shigenori ^a   Hashii, Yoshiko ^a   Sakai, Norio ^a   Taniike, Masako ^b   Ozono, Keiichi ^a   Hara, Junichi ^c  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Molecular Research Center for Children's Mental Development   (Japan)

^c OSAKA CITY GENERAL HOSPITAL   (Japan)

Author keywords

Busulfan; Cord blood transplantation; Cyclophosphamide; Fludarabine; Inherited metabolic disease

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; METHOTREXATE; METHYLPREDNISOLONE; MYELOABLATIVE AGENT; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADRENOLEUKODYSTROPHY; ARTICLE; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CORD BLOOD STEM CELL TRANSPLANTATION; FEASIBILITY STUDY; FEMALE; GLOBOID CELL LEUKODYSTROPHY; GRAFT VERSUS HOST REACTION; HEMORRHAGIC CYSTITIS; HUMAN; HUNTER SYNDROME; LYMPHOPROLIFERATIVE DISEASE; MALE; METABOLIC DISORDER; METACHROMATIC LEUKODYSTROPHY; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; NEUTROPHIL; POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER; PRESCHOOL CHILD; SCHOOL CHILD; SHORT COURSE THERAPY; TREATMENT INDICATION;

ADMINISTRATION, ORAL; BUSULFAN; CHILD, PRESCHOOL; CORD BLOOD STEM CELL TRANSPLANTATION; CYCLOPHOSPHAMIDE; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LYSOSOMAL STORAGE DISEASES; MALE; METHOTREXATE; PEROXISOMAL DISORDERS; VIDARABINE;

EID: 49349107320     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2007.00876.x     Document Type: Article

References (20)

1. Peters C, Steward CG. Hematopoietic cell transplantation for inherited metabolic diseases: An overview of outcomes and practice guidelines. Bone Marrow Transplant 2003: 31: 229 239.
2. Brady RO, Schiffmann R. Enzyme-replacement therapy for metabolic storage disorders. Lancet Neurology 2004: 3: 752 756.
3. Desnick RJ, Schuchman EH. Enzyme replacement and enhancement therapies: Lessons from lysosomal disorders. Nat Rev Genet 2002: 3: 954 966.
4. Krivit W. Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases. Springer Semin Immunopathol 2004: 26: 119 132.
5. Malatack JJ, Consolini DM, Bayever E. The status of hematopoietic stem cell transplantation in lysosomal storage disease. Pediatr Neurol 2003: 29: 391 403.
6. Martin PL, Carter SL, Kernan NA, et al. Results of the cord blood transplantation study (COBLT): Outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases. Biol Blood Marrow Transplant 2006: 12: 184 194.
7. Staba SL, Escolar ML, Poe M, et al. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med 2004: 350: 1960 1969.
8. Sauer M, Grewal S, Peters C. Hematopoietic stem cell transplantation for mucopolysaccharidoses and leukodystrophies. Klin Padiatr 2004: 216: 163 168.
9. Escolar ML, Poe MD, Provenzale JM, et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med 2005: 352: 2069 2081.
10. Chao NJ, Emerson SG, Weinberg KI. Stem cell transplantation (cord blood transplants). Hematology (Am Soc Hematol Educ Program) 2004: 354 371.
11. Morishima Y, Sasazuki T, Inoko H, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 2002: 99: 4200 4206.
12. Gluckman E, Rocha V, Chevret S. Results of unrelated umbilical cord blood hematopoietic stem cell transplant. Transfus Clin Biol 2001: 8: 146 154.
13. Gluckman E, Rocha V. Donor selection for unrelated cord blood transplants. Curr Opin Immunol 2006: 18: 565 570.
14. Young NS. Immunosuppressive treatment of acquired aplastic anemia and immune-mediated bone marrow failure syndromes. Int J Hematol 2002: 75: 129 140.
15. Resnick IB, Shapira MY, Slavin S. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases. Transpl Immunol 2005: 14: 207 219.
16. Jacobsohn DA, Duerst R, Tse W, Kletzel M. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet 2004: 364: 156 162.
17. Peters C, Balthazor M, Shapiro EG, et al. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 1996: 87: 4894 4902.
18. Fleming DR, Henslee-Downey PJ, Ciocci G, et al. The use of partially HLA-mismatched donors for allogeneic transplantation in patients with mucopolysaccharidosis-I. Pediatr Transplant 1998: 2: 299 304.
19. Gong JZ, Bayerl MG, Sandhaus LM, et al. Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children. Am J Surg Pathol 2006: 30: 328 336.
20. Brunstein CG, Weisdorf DJ, DeFor T, et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006: 108: 2874 2880.